ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR).

被引：0

作者：

Laccetti, Andrew Leonard

Smith, Matthew Raymond

Scher, Howard I.

Verholen, Frank

Adorjan, Patrick

Dissanayake, Manjari

Gao, Xin

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[3] Harvard Med Sch, Boston, MA USA

[4] Bayer Consumer Care AG, Basel, Switzerland

[5] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

261-436-2730; 3282-3221-2748-2527; 261-492-199-2823; 261-492-3532-2370-7650-2700; 613-615-646-2631; 261-137; 613-4678-146-349; 6; 5; 4; 3; 2; 60; 2946; 256; 38092-27011; 38092-27372; 38092-25779; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.TPS243

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS243 / TPS243

页数：1

共 10 条

[1] A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study
Gao, Xin
Smith, Matthew Raymond
Scher, Howard I.
Verholen, Frank
Adorjan, Patrick
Dissanayake, Manjari
Laccetti, Andrew Leonard
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)
Agarwal, N.
Azad, A. A.
Mateo, J.
Shore, N. D.
Chakrabarti, J.
Chen, H-C.
Lanzalone, S.
Niyazov, A.
Saad, F.
ANNALS OF ONCOLOGY, 2021, 32 : S672 - S673
[3] Pembrolizumab plus olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
Yu, E. Y.
Park, S. H.
Goh, J. C. H.
Shin, S. J.
Mehra, N.
McDermott, R.
Sala Gonzalez, M. A.
Fong, P. C.
Greil, R.
Retz, M.
Sade, J. P.
Huang, Y-H.
Begbie, S.
Rey, F.
Kramer, G.
Suzuki, H.
Zhang, J.
Kim, J.
Poehlein, C. H.
Antonarakis, E. S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1163 - S1164
[4] TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).
Agarwal, Neeraj
Saad, Fred
Azad, Arun
Mateo, Joaquin
Matsubara, Nobuaki
Shore, Neal D.
Chakrabarti, Jayeta
Chen, Hsiang-Chun
Lanzalone, Silvana
Niyazov, Alexander
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[5] A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)
Tombal, Bertrand F.
Gomez-Veiga, Francisco
Gomez-Ferrer, Alvaro
Lopez-Campos, Fernando
Ost, Piet
Roumeguere, Thierry Andre
Herrera-Imbroda, Bernardo
D'Hondt, Lionel A.
Quivrin, Magali
Gontero, Paolo
Villa, Salvador
Khaled, Hussein
Fournier, Beatrice
Musoro, Jammbe
Krzystyniak, Joanna
Pretzenbacher, Yassin
Loriot, Yohann
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (05): : 1051 - 1060
[6] A phase 2 randomized open-label study of oral darolutamide monotherapy vs. androgen deprivation therapy in men with hormone-naive prostate cancer (EORTC-GUCG 1532).
Tombal, Bertrand F.
Gomez-Veiga, Francisco
Gomez-Ferrer, Alvaro
Lopez-Campos, Fernando
Ost, Piet
Roumeguere, Thierry Andre
Herrera-Imbroda, Bernardo
D'Hondt, Lionel A.
Quivrin, Magali
Gontero, Paolo
Villa, Salvador
Khaled, Hussein Mustafa
Fournier, Beatrice
Krzystyniak, Joanna
Pretzenbacher, Yassin
Erkol, Hazal
Loriot, Yohann
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[7] PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study
Petrylak, Daniel P.
Vogelzang, Nicholas J.
Chatta, Kamal
Fleming, Mark T.
Smith, David C.
Appleman, Leonard J.
Hussain, Arif
Modiano, Manuel
Singh, Parminder
Tagawa, Scott T.
Gore, Ira
McClay, Edward F.
Mega, Anthony E.
Sartor, A. Oliver
Somer, Bradley
Wadlow, Raymond
Shore, Neal D.
Olson, William C.
Stambler, Nancy
DiPippo, Vincent A.
Israel, Robert J.
PROSTATE, 2020, 80 (01): : 99 - 108
[8] A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study.
Kilari, Deepak
Szabo, Aniko
Hall, William A.
Nelson, Ariel Ann
Johnson, Scott
Giever, Thomas A.
Burfeind, John
Tolat, Parag
Bylow, Kathryn A.
Iczkowski, Kenneth
Sun, Yunguang
Rui, Hallgeir
Thomas, James P.
Nevalainen, Marja
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[9] A randomized open-label phase 2a study evaluating the efficacy and safely of radium 223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
Petrylak, Daniel Peter
Rosenberg, Julie A.
Garosi, Vittorio Luigi
Siegel, Jonathan
Goldin, Jonathan
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[10] Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician's choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Ryan, Charles J.
Watkins, Simon Paul
Despain, Darrin
Karlovich, Chris Alan
Simmons, Andrew
Golsorkhi, Anthony A.
Chowdhury, Simon
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 →